Biosimilars open up new opportunities in chronic diseases-Reference-Cited by-同舟云学术

Biosimilars open up new opportunities in chronic diseases

Published:2021-03-20 Issue:1 Volume:1 Page:34-37
ISSN:2724-4296
Container-title:International Journal of Bone Fragility
language:
Short-container-title:Int J Bone Frag

Author:

Brandi Maria Luisa¹

Affiliation:

1. President of the National Observatory on Fragility Fractures

Abstract

The World Health Organization defines a biosimilar product as a biotherapeutic that is similar in terms of quality, safety and efficacy to an already licensed reference product available on the market. To ensure similar efficacy and safety, comparability studies for biosimilars should be carried out at quality, preclinical and clinical level. In this article we provide an overview of biosimilars, looking at the definition of the term biosimilar, the regulatory framework and the future prospects for these drugs. As biosimilar drugs will revolutionize the treatment of osteoporosis, this paper aims to evaluate the pros and cons of choosing the teriparatide biosimilar Movymia®, looking at whether it really can be considered clinically equivalent to the original drug. The benefits of biosimilars may include improving patient access and affordability. Off-patent biologics and biosimilars may also create market competition and stimulate incremental innovation by manufacturers.

Publisher

Medimay Communication

Link

https://www.journalbonefragility.com/wp-content/uploads/journal/2021/1.1/34-37.pdf

Reference11 articles.

1. 1. European Medicines Agency. Biosimilars in the EU, Information guide for healthcare professionals. 2017. Available at: http://ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf. Accessed February 5, 2019).

2. 2. U.S. Food & Drug Administration (FDA) - Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. April 2015. Available at: https://www.fda.gov/media/135612/download. Accessed February 5, 2019).

3. 3. Blauvelt A, Cohen AD, Puig L, Vender R, van der Walt J, Wu JJ. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. Br J Dermatol. 2016;174(2):282-6. https://doi.org/10.1111/bjd.14267

4. 4. Gupta SK, Chaudari PS, Nath R. Opportunities and challenges in biosimilar development. BioProcess International 2017. Available at: https://bioprocessintl.com/manufacturing/biosimilars/opportunitieschallenges-biosimilar-development/. Accessed February 5, 2019).

5. 5. Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU Biosimilar Framework: Past and Future. BioDrugs. 2019;33(6):621-34. https://doi.org/10.1007/s40259-019-00377-y